Navigation Links
Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy
Date:11/3/2009

WALTHAM, Mass, Nov. 3 /PRNewswire/ -- On-Q-ity, a next-generation oncology diagnostics company focused on improving cancer therapy effectiveness, announced today that it has closed a $21 million series A financing. The funding was led by MDV-Mohr Davidow Ventures and included Bessemer Venture Partners, Physic Ventures and Northgate Capital.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070702/AQM026LOGO)

On-Q-ity is developing diagnostics to determine optimal treatment choice for cancer patients at each stage of the treatment cycle - from the first therapy choice to monitoring for recurrence. The company's novel circulating tumor cell (CTC) technology and predictive biomarker platform allows for the analysis of tumor tissue samples as well as the capture of rare tumors cells that are circulating in a cancer patient's blood. Those cells are then monitored for molecular changes that are characteristic of therapy response. This combination enables minimally invasive real-time data on a patient's status - allowing treatment adjustments before changes are visible with any other technology.

Mara Aspinall is President and Chief Executive Officer of On-Q-ity and a leader in the fields of diagnostics, oncology and personalized medicine. Formerly president of Genzyme Genetics, she expanded the business' scope and market reach to become one of the nation's largest diagnostic laboratories. She described On-Q-ity's technology as a paradigm shift in cancer care, explaining, "We will enable physicians to confidently choose effective therapy and then actively monitor their patients' treatment response or resistance. By using CTCs and predictive DNA repair biomarkers, we can help quickly determine if a therapy is working and reduce the cost as well as the loss of critical time associated with ineffective treatments. Through ongoing personalized diagnosis, we hope to improve patient care and, ultimately, increase survival rates."

Sue Siegel, MDV Partner and On-Q-ity board member, added, "Mara has been at the forefront of personalized medicine and has a proven ability to bring new diagnostics to market. We are excited that the combination of a strong seasoned team and On-Q-ity's arsenal of proprietary technologies can play a key role in our nation's war on cancer and improve patient care while reducing healthcare costs."

In addition to Siegel, Steve Kraus from Bessemer Venture Partners and Dion Madsen from Physic Ventures will join the On-Q-ity board of directors.

About On-Q-ity

On-Q-ity is a next-generation diagnostics company focused on transforming cancer treatment and improving treatment outcomes for cancer patients. The Company is developing innovative diagnostics to identify the unique characteristics of an individual's cancer, predicting the response to therapy, and monitoring the progress of treatment. On-Q-ity was formed earlier this year through the merger of Cellective DX, a developer of microfluidics devices to detect and capture rare circulating tumor cells from the blood of cancer patients, with The DNA Repair Company, a molecular diagnostics company developing biomarker panels to predict response to cancer therapy based on DNA repair pathways in tumors.

The company's CTC and biomarker technologies originated from ground-breaking research at Massachusetts General Hospital and the Dana Farber Cancer Institute and MIT, respectively. The privately-held company, headquartered in Waltham, MA, is funded by Bessemer Venture Partners, MDV-Mohr Davidow Ventures, Physic Ventures and Northgate Capital. For more information, visit: www.On-Q-ity.com.

SOURCE MDV-Mohr Davidow Ventures


'/>"/>
SOURCE MDV-Mohr Davidow Ventures
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ScandiDos Sells 100th Delta4(R) PT Unit as Adoption of Rotational Therapy Cancer Treatment Increases
2. Reportlinker Adds Chinese Markets for Bladder Cancer Treatment Drugs
3. Obesity Significantly Increases Side Effects of Stereotactic Body Radiation Therapy in Lung Cancer Patients
4. superDimension Launches Second Generation iLogic(TM)Electromagnetic Navigation Bronchoscopy System to Detect and Diagnose Lung Cancer
5. Cancer Treatment Guidelines for Diverse Asian Economies Use Model Developed at Fred Hutchinson Cancer Research Center
6. High-Resolution Breast PET Improves Breast Cancer Detection
7. Breast Health is a Year-Round Priority: New Technology Identifies Risk of Breast Cancer in Younger Women
8. Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center
9. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
10. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
11. November is Lung Cancer Month: Know the Latest Information About This Deadliest of Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
Breaking Medicine News(10 mins):